McKesson Corporation $MCK Position Boosted by Titan Investment Management LLC

Titan Investment Management LLC increased its position in McKesson Corporation (NYSE:MCK) by 20.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,711 shares of the company’s stock after purchasing an additional 622 shares during the quarter. McKesson makes up 2.4% of Titan Investment Management LLC’s portfolio, making the stock its 12th biggest position. Titan Investment Management LLC’s holdings in McKesson were worth $3,168,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Nvwm LLC boosted its stake in shares of McKesson by 933.3% in the 3rd quarter. Nvwm LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing an additional 28 shares during the last quarter. Delos Wealth Advisors LLC acquired a new stake in shares of McKesson during the 2nd quarter worth approximately $27,000. Trellis Wealth Advisors LLC acquired a new stake in shares of McKesson during the 3rd quarter worth approximately $32,000. Clearstead Trust LLC bought a new stake in shares of McKesson during the second quarter worth approximately $37,000. Finally, GK Wealth Management LLC bought a new stake in shares of McKesson during the third quarter worth approximately $38,000. 85.07% of the stock is owned by institutional investors.

McKesson Trading Down 0.5%

McKesson stock opened at $1,010.85 on Friday. The firm has a market capitalization of $117.86 billion, a P/E ratio of 27.05, a PEG ratio of 2.02 and a beta of 0.30. McKesson Corporation has a 1 year low of $723.68 and a 1 year high of $1,030.27. The business has a 50-day moving average of $908.70 and a 200-day moving average of $841.27.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $9.93 EPS for the quarter, beating analysts’ consensus estimates of $9.56 by $0.37. The company had revenue of $105.38 billion during the quarter, compared to analysts’ expectations of $103.88 billion. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%. McKesson’s revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the business posted $8.26 EPS. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. Research analysts anticipate that McKesson Corporation will post 44.71 EPS for the current fiscal year.

McKesson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Investors of record on Tuesday, December 1st will be issued a dividend of $0.94 per share. The ex-dividend date is Tuesday, December 1st. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. McKesson’s payout ratio is currently 10.06%.

Key Stories Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Mizuho raised its price target for McKesson to $1,020, implying modest additional upside from recent trading levels. The upgrade follows the stock reaching a new one-year high and could support investor confidence. Mizuho raises McKesson price target
• Positive Sentiment: A recent analysis argues that artificial-intelligence initiatives and a potential FDA overhaul could become larger growth drivers for McKesson in 2027, potentially outweighing current regulatory headwinds. McKesson AI and FDA outlook
• Neutral Sentiment: McKesson declared a quarterly dividend of $0.94 per share, payable January 4, 2027, to shareholders of record December 1. The annualized payout is $3.76, representing a relatively low yield of about 0.4%, so the announcement is primarily a signal of continued shareholder returns rather than a major income catalyst. McKesson declares quarterly dividend
• Neutral Sentiment: Investor attention remains elevated after McKesson’s strong long-term performance and recent analyst upgrade, but elevated valuation and the stock’s proximity to its 52-week high may limit near-term upside. McKesson reaches one-year high
• Negative Sentiment: An insider, Francisco Fraga, reportedly sold 800 McKesson shares. The transaction is not necessarily a fundamental warning, but insider selling can weigh modestly on sentiment. McKesson insider share sale
• Negative Sentiment: Coverage of a McKesson-related security incident highlights potential cybersecurity and operational risks, which could add to investor concerns alongside regulatory uncertainty. McKesson security incident analysis

Insider Buying and Selling at McKesson

In other McKesson news, EVP Francisco Fraga sold 800 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $995.80, for a total value of $796,640.00. Following the completion of the sale, the executive vice president owned 5,423 shares of the company’s stock, valued at approximately $5,400,223.40. This represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO B Jr sold 111 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total transaction of $98,950.95. Following the completion of the sale, the chief accounting officer owned 521 shares in the company, valued at approximately $464,445.45. This trade represents a 17.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 1,212 shares of company stock valued at $1,164,182. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on MCK. TD Cowen increased their price objective on shares of McKesson from $989.00 to $1,006.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Weiss Ratings raised shares of McKesson from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, September 4th. Evercore reaffirmed an “outperform” rating and set a $950.00 target price (down from $1,000.00) on shares of McKesson in a report on Thursday, August 6th. Morgan Stanley set a $977.00 target price on shares of McKesson in a research report on Tuesday, October 6th. Finally, Leerink Partners increased their price target on McKesson from $1,030.00 to $1,070.00 and gave the company an “outperform” rating in a research note on Wednesday, October 7th. Fifteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, McKesson presently has an average rating of “Moderate Buy” and a consensus target price of $997.12.

About McKesson

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.